Liquidia (LQDA) Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LQDA Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Liquidia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$86.22 |
| 52 Week High | US$91.10 |
| 52 Week Low | US$16.82 |
| Beta | 0.55 |
| 1 Month Change | 10.30% |
| 3 Month Change | 129.00% |
| 1 Year Change | 335.02% |
| 3 Year Change | 1,016.84% |
| 5 Year Change | 3,553.39% |
| Change since IPO | 676.76% |
Recent News & Updates
LQDA: Pending Patent Outcomes Will Drive Future Earnings Upside Or Downside
Analysts lifted their fair value estimate for Liquidia to $60.00 from $16.99, citing higher Street price targets, stronger conviction in Yutrepia's potential positioning in PAH and PH-ILD, and updated assumptions around earnings power and legal outcomes. These changes are reflected in revised discount rate, margin, and future P/E inputs.
LQDA: Legal Outcomes Around Key Patent Will Drive Future Upside
Analysts have lifted their implied fair value estimate for Liquidia from about $67.00 to roughly $103.00, citing updated models that reflect stronger expectations for Yutrepia, higher peak sales assumptions up to $2.2b, and legal outcomes that they view as better framed after recent court decisions. Some now prefer to wait for more clarity on key patent litigation before assuming further upside.Recent updates
LQDA: Pending Patent Outcomes Will Drive Future Earnings Upside Or Downside
Analysts lifted their fair value estimate for Liquidia to $60.00 from $16.99, citing higher Street price targets, stronger conviction in Yutrepia's potential positioning in PAH and PH-ILD, and updated assumptions around earnings power and legal outcomes. These changes are reflected in revised discount rate, margin, and future P/E inputs.LQDA: Legal Outcomes Around Key Patent Will Drive Future Upside
Analysts have lifted their implied fair value estimate for Liquidia from about $67.00 to roughly $103.00, citing updated models that reflect stronger expectations for Yutrepia, higher peak sales assumptions up to $2.2b, and legal outcomes that they view as better framed after recent court decisions. Some now prefer to wait for more clarity on key patent litigation before assuming further upside.
LQDA: Legal Outcomes And Earnings Power Will Shape The Next Phase
Analysts have lifted the updated fair value estimate for Liquidia to $72.38 from $44.00, as higher assumed profit margins, a lower future P/E multiple, and evolving views on legal and earnings risk reshape their price target frameworks. Analyst Commentary Recent Street research on Liquidia highlights a mix of enthusiasm around potential earnings power and caution around legal outcomes, which together shape how analysts think about valuation and execution risk.Liquidia (LQDA) Stock Could Be 63.2% Overvalued After PHA 2026 YUTREPIA Update
Liquidia (LQDA) is back in focus after the company outlined four new poster presentations at the PHA 2026 International PH Conference, spotlighting fresh YUTREPIA data and broader pulmonary hypertension care insights. See our latest analysis for Liquidia. The PHA 2026 conference update comes at a time when Liquidia’s momentum has been strong, with a 30 day share price return of 26.12% and a 5 year total shareholder return of 2,737.94%. Together, these figures point to sentiment that has...Upgrade: Analysts Just Made A Captivating Increase To Their Liquidia Corporation (NASDAQ:LQDA) Forecasts
Shareholders in Liquidia Corporation ( NASDAQ:LQDA ) may be thrilled to learn that the analysts have just delivered a...Liquidia: Big Q3 Sales Print, But Voucher Starts And Inventory Can Distort Optics
Summary Liquidia (LQDA) has rebounded with YUTREPIA's FDA approval and $51.7M in Q3 net product sales, but valuation remains fragile. Current sales and script numbers are influenced by channel inventory, GTN estimates, and free voucher programs, casting uncertainty on true patient demand and revenue durability. Litigation risk persists, particularly regarding United Therapeutics' patents, with outcomes that could significantly impact YUTREPIA's commercial footprint. I maintain a Sell rating on LQDA, citing unresolved litigation, uncertain real-world uptake, and a valuation that prices in substantial future success. Read the full article on Seeking AlphaLiquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump
Liquidia Corporation ( NASDAQ:LQDA ) shares have had a really impressive month, gaining 30% after a shaky period...Is Liquidia (NASDAQ:LQDA) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Liquidia Corporation's Long-Running Saga Is Coming To An End
Summary Today, we are circling back on Liquidia Corporation, as its long-running litigation battle with United Therapeutics is finally coming to a positive end. This means we will likely see the full commercial launch of its primary candidate, YUTREPIA before the end of the second market. YUTREPIA is targeting a large potential market and could garner significant market share. An updated analysis around Liquidia Corporation follows in the paragraphs below. Read the full article on Seeking AlphaShareholder Returns
| LQDA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 11.9% | 1.9% | -1.0% |
| 1Y | 335.0% | 42.9% | 14.7% |
Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 42.9% over the past year.
Return vs Market: LQDA exceeded the US Market which returned 14.7% over the past year.
Price Volatility
| LQDA volatility | |
|---|---|
| LQDA Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LQDA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LQDA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 216 | Roger Jeffs | www.liquidia.com |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia Corporation Fundamentals Summary
| LQDA fundamental statistics | |
|---|---|
| Market cap | US$7.67b |
| Earnings (TTM) | US$22.31m |
| Revenue (TTM) | US$288.07m |
Is LQDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LQDA income statement (TTM) | |
|---|---|
| Revenue | US$288.07m |
| Cost of Revenue | US$23.58m |
| Gross Profit | US$264.49m |
| Other Expenses | US$242.18m |
| Earnings | US$22.31m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 91.82% |
| Net Profit Margin | 7.74% |
| Debt/Equity Ratio | 163.8% |
How did LQDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/27 04:54 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Liquidia Corporation is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Julian Harrison | BTIG |
| Andrew Fein | H.C. Wainwright & Co. |